Also listed on Aralez Pharmaceuticals Trading Dac, an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Aug 20, 2027 · Medium confidence
20-year base term ends Aug 20, 2027
Why Medium: A parent in the chain could not be resolved.
Held by Rosemont Pharmaceuticals LLC
Filed Jun 18, 2008 as application 12/141,280 · Granted Mar 29, 2011
Base term plus 82 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
2007
2027
Clock starts
Aug 20, 2007
Aug 20, 2007
Term ends
Aug 20, 2027
Aug 20, 2027
Granted
Mar 29, 2011
Mar 29, 2011
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
82
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 7,569,612.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
7
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 82 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. All three maintenance fees are recorded paid; no more fees are due. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Aug 20, 2007, when application 11/841,328, the earliest non-provisional in its chain, was filed (this one was filed Jun 18, 2008); a parent in its chain could not be resolved (the next row) | Aug 20, 2027 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | +82 days, USPTO patent term adjustment record | Nov 10, 2027 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,569,612) | capped to Aug 20, 2027 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Aug 20, 2027 | Medium confidence |
This family
| US 7,569,612 | In force (reinstated) Aug 2027 | Aug 2027 |
| US 7,915,247 | this patent Aug 2027 | Aug 2027 |
| US 7,741,373 | In force Aug 2027 | Aug 2027 |
| US 7,741,374 | In force Aug 2027 | Aug 2027 |
4 of 7 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Mar 18, 2009 Reel 22414, frame 719 | Mutual Pharmaceutical Company, Inc. | UBS AG, Stamford Branch, as Collateral Agent | Patent Security Agreement |
| Apr 14, 2011 Reel 26125, frame 855 | Mutual Pharmaceutical Company, Inc. | Ar Holding Company, Inc. | Assignment of Assignor's Interest |
| Aug 15, 2011 Reel 26747, frame 703 | UBS AG, Stamford Branch, a Swiss Banking Institution | Mutual Pharmaceutical Company, Inc., a Pennsylvania Corporation | Release of Security Interest |
| Nov 30, 2012 Reel 29378, frame 850 | Ar Holding Company, Inc. | MPC Oldco, Inc. | Merger |
| Dec 26, 2012 Reel 29526, frame 361 | MPC Oldco, Inc. | Mutual Pharmaceutical Company, Inc. | Assignment of Assignor's Interest |
| May 22, 2015 Reel 35700, frame 819 | Mutual Pharmaceutical Company, Inc. | Tribute Pharmaceuticals International Inc. | Assignment of Assignor's Interest |
| Jun 2, 2015 Reel 35831, frame 513 | Mutual Pharmaceutical Company, Inc. | Tribute Pharmaceuticals International Inc. | Corrective Assignment to Correct the Jurisdiction of Incorporation Previously Recorded on Reel 035700 Frame 0819. Assignor(S) Hereby Confirms the Assignment. |
| Dec 21, 2016 Reel 41091, frame 860 | Tribute Pharmaceuticals International Inc. | Aralez Pharmaceuticals Trading Dac | Nunc Pro Tunc Assignment |
| Aug 24, 2018 Reel 46696, frame 772 | Aralez Pharmaceutical Trading Dac | Deerfield Management Company, L.P., as Administrative Agent | Security Interest |
| Aug 30, 2018 Reel 46988, frame 741 | Aralez Pharmaceuticals Trading Designated Activity Company | Deerfield Management Company, L.P., as Administrative Agent | Corrective Assignment to Correct the Conveying Party Previously Recorded at Reel: 046696 Frame: 0772. Assignor(S) Hereby Confirms the Assignment. |
| Feb 20, 2019 Reel 48386, frame 902 | Deerfield Management Company L.P. | Aralez Pharmaceuticals Trading Designated Activity Company | Release of Security Interest |
| Apr 18, 2019 Reel 48930, frame 107 | Aralez Pharmaceuticals Trading Dac | Athena Bioscience, LLC | Assignment of Assignor's Interest |
| Oct 29, 2025 Reel 72722, frame 333 | Athena Bioscience, LLC; Rosemont Pharmaceuticals LLC; Palmetto Pharmaceuticals, LLC | Glas Trust Corporation Limited, as Security Agent | Security Interest |
| Dec 22, 2025 Reel 73287, frame 566 | Athena Bioscience, LLC | Rosemont Pharmaceuticals LLC | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Aug 2027
Term ends Aug 20, 2027. No further fees fall due before then
Note
The 82 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 7,569,612.
Citations
6
later US patents cite this one
That is below the median of utility patents granted in 2011 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.